Cargando…
Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection
Chronic infection with hepatitis B virus (HBV) occurs in approximately 6% of the world's population and carriers of the virus are at risk for hepatocellular carcinoma and cirrhosis. Current treatment regimens, which include interferon-α and nucleoside/nucleotide analogs, are only partially effe...
Autores principales: | Weinberg, Marc S, Arbuthnot, Patrick |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873806/ https://www.ncbi.nlm.nih.gov/pubmed/20429960 http://dx.doi.org/10.1186/gm149 |
Ejemplares similares
-
Advances with RNAi-Based Therapy for Hepatitis B Virus Infection
por: van den Berg, Fiona, et al.
Publicado: (2020) -
Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach
por: Singh, Prashika, et al.
Publicado: (2021) -
ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells
por: Scott, Tristan, et al.
Publicado: (2017) -
RNA interference as a novel treatment strategy for chronic hepatitis B infection
por: Hui, Rex Wan-Hin, et al.
Publicado: (2022) -
RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
por: Yuen, Man‐Fung, et al.
Publicado: (2020)